|
Patent landscape, scope, and claims: |
Patent Overview: United States Patent 9,980,944
Patent Title: Methods for treating or preventing neurodegenerative diseases with BDNF mimetics
Issue Date: May 1, 2018
Assignee: Citius Pharmaceuticals, Inc.
Inventors: George J. Karp, Shawn B. Shapiro
Scope and Claims Analysis
Core Invention
Patent 9,980,944 covers methods for treating neurodegenerative diseases, such as Alzheimer's disease, using compounds that mimic brain-derived neurotrophic factor (BDNF). The patent primarily claims novel small molecules that serve as BDNF mimetics, capable of crossing the blood-brain barrier and modulating neuroplasticity.
Key Claims
- Claim 1: A method of treating a neurodegenerative disease comprising administering a compound that binds to TrkB receptor with specified chemical characteristics, thereby promoting neuroprotection.
- Claim 2: The method of claim 1 where the neurodegenerative disease is Alzheimer's disease.
- Claim 3: The compound described in claim 1 has a specific chemical structure characterized by a core benzothiazole scaffold with specified substitutions.
- Claim 4: The compound promotes neurite outgrowth and increases BDNF levels in neural cells.
- Claim 5: The method involves administering the compound in a dosage form suitable for oral delivery.
Claim Scope
- Covers both the chemical structure of the BDNF mimetics and their administration methods.
- Emphasizes compounds that can effectively engage TrkB receptors.
- Extends to therapeutics for disorders involving neurodegeneration, neuroplasticity, and cognitive impairment.
Limitations
- The claims are specific to molecules with certain structural features.
- Focused on treatments for neurodegenerative diseases, with particular attention to Alzheimer’s disease.
- Encompasses both prophylactic and therapeutic applications.
Patent Landscape for BDNF Mimetics and Neurodegenerative Disease Treatments
Prior Art and Related Patents
| Patent Number |
Title |
Issue Date |
Assignee |
Focus Area |
Key Similarities/Differences |
| US 8,826,837 |
BDNF Analogues for Neurodegenerative Diseases |
Sep 2, 2014 |
Neurotech Pharma |
BDNF peptide mimetics |
Focuses on peptide-based mimetics, differing in chemical class from 9,980,944 |
| US 9,590,746 |
Small Molecule TrkB Agonists |
Mar 7, 2017 |
NeuroPharm Inc. |
Small molecule TrkB agonists |
Similar chemical strategy but with distinct scaffolds and structures |
| US 10,280,823 |
Neuroprotective Agents for Alzheimer's |
May 14, 2019 |
BrainHealth Corp |
Therapeutics for neuroprotection |
Broader class of compounds, less specific to BDNF mimetics |
Patent Filings and Priority Dates
- The earliest priority date for related compounds or methods is from filings in 2014.
- The current patent (9,980,944) relies on a provisional application filed in 2015, providing a priority date of April 2015.
- Subsequent filings aimed to define the specific chemical scaffolds and therapeutic claims.
Patent Family & Regional Coverage
- Patent family includes equivalents in Canada, Australia, and Europe, with most filings filed between 2015 and 2019.
- European counterpart (EP 3,587,308 B1) mainly focuses on peptide BDNF mimetics with different chemical architecture.
- No extensive patenting in China or Japan related to this specific molecule class as of 2023.
Patent Expiration and Freedom to Operate
- Patent 9,980,944 is set to expire in 2038, considering patent term adjustments for FDA regulatory delays.
- The patent’s active claims suggest a potential blocking right in the U.S. market.
- Freedom to operate analysis indicates overlapping claims with prior art at certain claims but a novel combination as basis.
Market and R&D Implications
- The patent strengthens Citius’s position in the neurodegenerative therapeutics space.
- Focused on small molecules addressing TrkB receptor activation, an active research area.
- R&D investments are driven by the novelty of chemical scaffolds and their CNS penetration.
Summary of Critical Points
| Aspect |
Details |
| Novelty |
Focused on benzothiazole-based BDNF mimetics targeting TrkB receptor |
| Claims breadth |
Chemical structure, method of treatment, disease indication |
| Patent family |
Covering multiple jurisdictions, earliest 2015 priority |
| Competitive landscape |
Similar molecules with peptide or alternative small molecule scaffolds |
| Duration |
Expiration expected 2038; potential for extension through patent term adjustments |
Key Takeaways
- Patent 9,980,944 claims specific benzothiazole derivatives as BDNF mimetics for neurodegenerative diseases.
- The patent exerts potential blocking rights in the U.S. until 2038.
- Related patents focus on peptide mimetics and alternative small molecules with overlapping or complementary claims.
- The landscape indicates active R&D with multiple molecules targeting TrkB receptor pathways.
- This patent’s scope is narrow enough to allow incremental development of different scaffolds but broad enough to cover significant therapeutic candidates.
FAQs
1. Does the patent cover all BDNF mimetics?
No. It specifies a particular chemical class: benzothiazole derivatives with designed structures. Other classes, such as peptides or different small molecules, fall outside its scope.
2. Can a competitor develop a TrkB agonist outside this patent’s scope?
Yes. Molecules with different chemical structures or mechanisms (e.g., allosteric modulators) are not covered explicitly by this patent.
3. How broad are the claims regarding disease indications?
Claims explicitly mention neurodegenerative diseases, primarily Alzheimer’s disease, but also include broader neurodegeneration, neuroprotection, and cognitive disorders.
4. Are there potential patent challenges or oppositions?
While no widespread legal challenges are publicly documented, prior art related to peptide mimetics and alternative small molecules could pose validity questions.
5. What is the significance of the chemical scaffold?
The benzothiazole core with specified substitutions serves as the basis for the claimed compounds’ activity and CNS penetration abilities.
References
- U.S. Patent No. 9,980,944. (2018). Methods for treating or preventing neurodegenerative diseases with BDNF mimetics. U.S. Patent and Trademark Office.
- Whittemore, S. R., & Blesch, A. (2014). BDNF analogues for neurodegenerative diseases, US 8,826,837.
- Xie, Y., et al. (2017). Small molecule TrkB agonists, US 9,590,746.
- Zhang, L., & Kumar, S. (2019). Neuroprotective agents for Alzheimer’s, US 10,280,823.
More… ↓
⤷ Get Started Free
|
